Abstracts tagged "psoriatic arthritis and registry"

Abstract Number: 2869 • 2015 ACR/ARHP Annual Meeting
Impact of Methotrexate on the Real-World Effectiveness of Golimumab in Psoriatic Arthritis
Louis Bessette¹, Proton Rahman², Denis Choquette³, John Kelsall⁴, Maqbool Sheriff⁵, Emmanouil Rampakakis⁶, Eliofotisti Psaradellis⁷, Allen J Lehman⁸, Karina Maslova⁸, Francois Nantel^9,10, Brendan Osborne¹¹ and Cathy Tkaczyk¹¹, ¹Centre d’Ostéoporose et de Rhumatologie de Québec (CORQ), Québec, QC, Canada, ²Medicine, Memorial University, St John's, NF, Canada, ³Rheumatology Department, Institut de Rhumatologie de Montréal and University of Montreal, Montreal, QC, Canada, ⁴Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, Canada, ⁵Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁶JSS Medical Research, St-Laurent, QC, Canada, ⁷JSS Medical Research, Montreal, QC, Canada, ⁸Janssen Inc., Toronto, ON, Canada, ⁹Schering Plough Canada Inc., Janssen Inc., Kirkland, QC, QC, Canada, ¹⁰19 Green belt Dr, Janssen Inc., Toronto, ON, Canada, ¹¹Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: : Previous controlled clinical trials have shown that concurrent methotrexate (MTX) therapy may enhance the efficacy of anti-TNF agents. However, real-world data on the…
Abstract Number: 2870 • 2015 ACR/ARHP Annual Meeting
Predictors of Early Minimal Disease Activity in Psa Patients Treated with Anti-TNF in a Real-World Registry
Michel Zummer¹, Proton Rahman², Regan Arendse³, Michael Starr⁴, John Kelsall⁵, J Antonio Avina-Zubieta⁶, Philip Baer⁷, Dalton Sholter⁸, Michelle Teo⁹, Emmanouil Rampakakis¹⁰, Eliofotisti Psaradellis¹¹, Brendan Osborne¹², Karina Maslova¹³, Francois Nantel¹⁴, Allen J Lehman¹³ and Cathy Tkaczyk¹², ¹Rheumatology, Hôpital Maisonneuve-Rosemont and University of Montreal, Montreal, QC, Canada, ²Medicine, Memorial University, St John's, NF, Canada, ³University of Saskatchewan, Saskatoon, SK, Canada, ⁴Rheumatology, McGill University, Montreal, QC, Canada, ⁵Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, Canada, ⁶Arthritis Research Canada / University of British Columbia, Vancouver, BC, Canada, ⁷Section on Rheumatology, Ontario Medical Association/Journal of the Canadian Rheumatology Association, Toronto, ON, Canada, ⁸Rheumatology Associates, Edmonton, AB, Canada, ⁹Rheumatology, Penticton Regional Hospital, Penticton, BC, Canada, ¹⁰JSS Medical Research, St-Laurent, QC, Canada, ¹¹JSS Medical Research, Montreal, QC, Canada, ¹²Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹³Janssen Inc., Toronto, ON, Canada, ¹⁴19 Green belt Dr, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Early achievement of minimal disease activity (MDA) is recommended as a valid treat-to-target approach in psoriatic arthritis (PsA). The purpose of the current analysis…
Abstract Number: 2877 • 2015 ACR/ARHP Annual Meeting
What Is the Location of Enthesitis in Ankylosing Spondylitis and Psoriatic Arthritis Patients and How Do They Respond to Anti-TNF Treatment?
John Kelsall¹, Denis Choquette², Proton Rahman³, Regan Arendse⁴, Michelle Teo⁵, Isabelle Fortin⁶, J Antonio Avina-Zubieta⁷, Emmanouil Rampakakis^8,9, Eliofotisti Psaradellis⁹, Karina Maslova¹⁰, Brendan Osborne¹¹, Cathy Tkaczyk¹¹, Francois Nantel¹² and Allen J Lehman¹⁰, ¹Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, Canada, ²Rheumatology Department, Institut de Rhumatologie de Montréal and University of Montreal, Montreal, QC, Canada, ³Medicine, Memorial University, St John's, NF, Canada, ⁴University of Saskatchewan, Saskatoon, SK, Canada, ⁵Rheumatology, Penticton Regional Hospital, Penticton, BC, Canada, ⁶Centre de Rhumatologie de l'Est du Québec, Rimouski, QC, Canada, ⁷Arthritis Research Canada, Richmond, BC, Canada, ⁸JSS Medical Research, St-Laurent, QC, Canada, ⁹JSS Medical Research, Montreal, QC, Canada, ¹⁰Janssen Inc., Toronto, ON, Canada, ¹¹Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹²19 Green belt Dr, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Enthesitis is characterized by inflammation at the insertion of ligaments, tendons, joint capsule, or fascia to bone, and represents a well-known characteristic feature of…
Abstract Number: 1551 • 2014 ACR/ARHP Annual Meeting
Correlation of Individual HAQ Questions with Disease Activity Measures in Psoriatic Arthritis: Implications for Instrument Reduction
Denis Choquette¹, Carter Thorne², Majed Khraishi³, Isabelle Fortin⁴, Regan Arendse⁵, Andrew Chow⁶, John Kelsall⁷, Milton Baker⁸, Julie Vaillancourt⁹, John S. Sampalis⁹, Francois Nantel¹⁰, Allen J Lehman¹¹, Susan Otawa¹¹ and May Shawi¹⁰, ¹Rheumatology, Notre Dame Hospital, Montreal, QC, Canada, ²Southlake Regional Health Centre, Newmarket, ON, Canada, ³Nexus Clinical Research, St John's, NF, Canada, ⁴Centre de Rhumatologie de l'Est du Québec, Rimouski, QC, Canada, ⁵University of Saskatchewan, Saskatoon, SK, Canada, ⁶University of Toronto, McMaster University, Credit Valley Rheumatology, Mississauga, ON, Canada, ⁷The Mary Pack Arthritis Centre, Vancouver, BC, Canada, ⁸University of Victoria, Victoria, BC, Canada, ⁹JSS Medical Research, Montreal, QC, Canada, ¹⁰Janssen Inc., Toronto, ON, Canada, ¹¹Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose The Health Assessment Questionnaire (HAQ) is commonly used for assessing patient-reported functional status and disease activity in psoriatic arthritis (PsA). However, it has been…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].